Brexpiprazole Orally Disintegrating Tablets 1mg (Rexulti® / レキサルティOD錠1mg)

JPY ¥27,000

Japanese Antipsychotic (Brexpiprazole 1mg). Oral once-daily tablet for schizophrenia, depression with inadequate response to existing treatment, and agitation/aggression in Alzheimer’s disease dementia. 100 tablets (10 tablets x 10). Mfd. by Otsuka Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥24,840
10 - 19 12% JPY ¥23,760
20 + 18% JPY ¥22,140
SKU: REX-1-TAB Category:

Description

Product Overview / 商品概要

Rexulti OD Tablets 1mg (レキサルティOD錠1mg)
Generic: Brexpiprazole / ブレクスピプラゾール
Therapeutic Category: Antipsychotic / 抗精神病薬
Manufactured by: Otsuka Pharmaceutical Co., Ltd. / 大塚製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Brexpiprazole 1mg per tablet / 1錠中 ブレクスピプラゾール 1mg
Additives: D-Mannitol, Microcrystalline cellulose, Low-substituted hydroxypropylcellulose, Partially pregelatinized starch, Sucralose, Yellow ferric oxide, Corn starch, Sodium stearyl fumarate, Magnesium stearate / D-マンニトール、結晶セルロース、低置換度ヒドロキシプロピルセルロース、部分アルファー化デンプン、スクラロース、黄色三二酸化鉄、トウモロコシデンプン、フマル酸ステアリルナトリウム、ステアリン酸マグネシウム
Appearance: Light yellow plain tablet, diameter 6mm, thickness 2.7mm, weight approx. 90mg
外観: 淡黄色の素錠、直径6mm、厚さ2.7mm、重さ約90mg

Indications / 効能効果

EN: Schizophrenia / Depression and depressive states (limited to cases where existing treatments have not provided sufficient effect) / Hyperactivity or aggressive behavior caused by agitation, irritability, and excitation associated with Alzheimer’s disease dementia
JA: 統合失調症/うつ病・うつ状態(既存治療で十分な効果が認められない場合に限る)/アルツハイマー型認知症に伴う焦燥感、易刺激性、興奮に起因する、過活動又は攻撃的言動

Dosage and Administration / 用法用量

EN: Usually, in adults, start with 1mg once daily as brexpiprazole, then increase the dose at intervals of at least 4 days to 2mg once daily orally. Usually, in adults, administer 1mg of brexpiprazole once daily orally. If tolerability is not an issue and sufficient effect is not observed, the daily dose may be increased to 2mg. Usually, in adults, start with 0.5mg once daily as brexpiprazole, then increase the dose at intervals of at least 1 week to 1mg once daily orally. If tolerability is not an issue and sufficient effect is not observed, the dose may be increased to 2mg once daily, with dose increases made at intervals of at least 1 week.
JA: 〈統合失調症〉通常、成人にはブレクスピプラゾールとして1日1回1mgから投与を開始した後、4日以上の間隔をあけて増量し、1日1回2mgを経口投与する。〈うつ病・うつ状態(既存治療で十分な効果が認められない場合に限る)〉通常、成人にはブレクスピプラゾールとして1日1回1mgを経口投与する。なお、忍容性に問題がなく、十分な効果が認められない場合に限り、1日量2mgに増量することができる。〈アルツハイマー型認知症に伴う焦燥感、易刺激性、興奮に起因する、過活動又は攻撃的言動〉通常、成人にはブレクスピプラゾールとして1日1回0.5mgから投与を開始した後、1週間以上の間隔をあけて増量し、1日1回1mgを経口投与する。なお、忍容性に問題がなく、十分な効果が認められない場合に限り、1日1回2mgに増量することができるが、増量は1週間以上の間隔をあけて行うこと。

Contraindications / 禁忌

EN: Patients in a comatose state / Patients under the strong influence of central nervous system depressants such as barbituric acid derivatives or anesthetics / Patients receiving adrenaline (except when used for emergency treatment of anaphylaxis or for infiltration or conduction anesthesia in dentistry) / Patients with a history of hypersensitivity to any component of this product
JA: 昏睡状態の患者/バルビツール酸誘導体・麻酔剤等の中枢神経抑制剤の強い影響下にある患者/アドレナリンを投与中の患者(アナフィラキシーの救急治療、又は歯科領域における浸潤麻酔もしくは伝達麻酔に使用する場合を除く)/本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 30300AMX00430
Sales Started: November 2021 / 2021年11月
Classification Code: 871179
Storage: Store at room temperature / 室温保存
Shelf Life: 36 months / 36箇月

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 500 tablets (10 tablets x 50) / Plastic bottle: 500 tablets (bulk, with desiccant)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Brexpiprazole Orally Disintegrating Tablets 1mg (Rexulti® / レキサルティOD錠1mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Brexpiprazole Orally Disintegrating Tablets 1mg (Rexulti®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.